{
    "clinical_study": {
        "@rank": "109432", 
        "arm_group": {
            "arm_group_label": "Lacosamide", 
            "arm_group_type": "Experimental", 
            "description": "Open-label, single-arm"
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate the long-term safety and tolerability of Lacosamide (LCM) 200\n      mg/day to LCM 600 mg/day taken in monotherapy in Japanese subjects who currently have\n      partial-onset seizures with or without secondary generalization and who are treated with a\n      single Anti-Epileptic Drug (AED) with marketing approval in Japan."
        }, 
        "brief_title": "A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Epilepsy", 
            "Partial-onset Seizures"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Epilepsy", 
                "Seizures"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is male or female and \u226516 years of age\n\n          -  Subject has a diagnosis of epilepsy, having experienced unprovoked partial-onset\n             seizures (IA, IB, or IC with clear focal origin) that are classifiable according to\n             the International League Against Epilepsy (ILAE) Classification of Epileptic\n             Seizures, 1981\n\n          -  Subject experiences partial-onset seizures despite appropriately chosen and\n             adequately tried treatment with 1 antiepileptic drug (AED)\n\n          -  Subject has been treated for epilepsy with a stable dose of 1 marketed AED The use of\n             benzodiazepines is permitted as rescue therapy for epilepsy. Benzodiazepines may have\n             been used as needed but not more frequently than once per week.\n\n        Exclusion Criteria:\n\n          -  Subject has a history or presence of seizures of other types than partial onset (IA,\n             IB, or IC with clear focal origin)\n\n          -  Subject is taking benzodiazepines for a nonepilepsy indication (Exception:\n             Concomitant use of benzodiazepines is allowed if the subject is taking them on a\n             regular basis, has been on a stable dose for at least 1 month prior to Visit 1, and\n             does not require changes in the dosage and administration throughout the study\n             period. However, concomitant use of benzodiazepines on an as needed basis is not\n             permitted.)\n\n          -  Female subject who is pregnant or nursing, and/or a woman of childbearing potential\n             who is not surgically sterile, 2 years postmenopausal or does not practice 1 highly\n             effective method of contraception, unless sexually abstinent, for the duration of the\n             study\n\n          -  Female subject of childbearing potential taking enzyme-inducing antiepileptic drugs\n             (EI-AEDs: CBZ, phenytoin, barbiturates, primidone, topiramate) who is not surgically\n             sterile, 2 years postmenopausal or does not practice 1 highly effective method of\n             contraception according to the World Health Organization (WHO) recommendation (ie,\n             depot medroxyprogesterone acetate, norethisterone enantate, intrauterine devices,\n             combined injectables, and progestogen implants) with administration of EI-AEDs or\n             does not practice 2 combined methods of contraception (ie, combined hormonal\n             contraception plus barrier method with spermicidal agent), unless sexually abstinent,\n             for the duration of the study\n\n          -  Subject has sick sinus syndrome without a pacemaker, or a second  or third degree\n             atrioventricular (AV) block, or subject has any other clinically relevant\n             electrocardiogram (ECG) abnormalities\n\n          -  Subject has a history of convulsive status epilepticus within the last 12 months\n             prior to Visit 1"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02124564", 
            "org_study_id": "EP0057"
        }, 
        "intervention": {
            "arm_group_label": "Lacosamide", 
            "description": "Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.\n4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .\nThe AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day.", 
            "intervention_name": "Lacosamide", 
            "intervention_type": "Drug", 
            "other_name": "Vimpat"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lacosamide", 
            "Epilepsy", 
            "Focal, Partial-Onset Seizures with or without secondary generalization", 
            "Monotherapy"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Asaka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "5"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamamatsu", 
                        "country": "Japan"
                    }, 
                    "name": "1"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Itami-shi", 
                        "country": "Japan"
                    }, 
                    "name": "11"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kagoshima", 
                        "country": "Japan"
                    }, 
                    "name": "6"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kamakura", 
                        "country": "Japan"
                    }, 
                    "name": "7"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miyakonojo-shi", 
                        "country": "Japan"
                    }, 
                    "name": "3"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-shi", 
                        "country": "Japan"
                    }, 
                    "name": "10"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nara", 
                        "country": "Japan"
                    }, 
                    "name": "2"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shizuoka", 
                        "country": "Japan"
                    }, 
                    "name": "4"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toyonaka", 
                        "country": "Japan"
                    }, 
                    "name": "9"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Multicenter, Open-Label, Long-Term Study to Investigate the Safety of Conversion to Lacosamide at Doses up to 600 mg/Day as Monotherapy in Japanese Adults With Partial-Onset Seizures With or Without Secondary Generalization", 
        "overall_contact": {
            "last_name": "UCB Clinical Trial Call Center", 
            "phone": "+1 877 822 9493"
        }, 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of Treatment-Emergent Adverse Events (TEAEs) during the study", 
                "safety_issue": "No", 
                "time_frame": "From the Titration Period (investigational product is taken) to the End of Study Visit (up to 2.5 years)"
            }, 
            {
                "measure": "Subject withdrawals due to Adverse Events (AEs) during the study", 
                "safety_issue": "No", 
                "time_frame": "From the Titration Period (investigational product is taken) to the End of Study Visit (up to 2.5 years)"
            }, 
            {
                "measure": "Serious Adverse Events (SAEs) during the study", 
                "safety_issue": "No", 
                "time_frame": "From the Titration Period (investigational product is taken) to the End of Study Visit (up to 2.5 years)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02124564"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects remaining seizure free for 6 consecutive months during the Monotherapy Period", 
                "safety_issue": "No", 
                "time_frame": "From the beginning of the Monotherapy Period  to the end of the Follow-Up Period (up to 2.5 years until the time of approval granted)"
            }, 
            {
                "measure": "Proportion of subjects remaining seizure free for 12 consecutive months during the Monotherapy Period", 
                "safety_issue": "No", 
                "time_frame": "From the beginning of the Monotherapy Period  to the end of the Follow-Up Period (up to 2.5 years until the time of approval granted)"
            }, 
            {
                "measure": "Time to discontinuation is evaluated as time to withdrawal of treatment due to AE or lack of efficacy (LOE) in the Monotherapy Period", 
                "safety_issue": "No", 
                "time_frame": "From the beginning of the Monotherapy Period  to the end of the Follow-Up Period (up to 2.5 years until the time of approval granted)"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB Japan Co. Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}